Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Simultaneous determination of post-translational racemization and isomerization of N-terminal amyloid-β in Alzheimer's brain tissues by covalent chiral derivatized ultraperformance liquid chromatography tandem mass spectrometry.

Inoue K, Hosaka D, Mochizuki N, Akatsu H, Tsutsumiuchi K, Hashizume Y, Matsukawa N, Yamamoto T, Toyo'oka T.

Anal Chem. 2014 Jan 7;86(1):797-804. doi: 10.1021/ac403315h.

PMID:
24283798
2.

Quantitative analysis of amyloid beta peptides in cerebrospinal fluid of Alzheimer's disease patients by immunoaffinity purification and stable isotope dilution liquid chromatography/negative electrospray ionization tandem mass spectrometry.

Oe T, Ackermann BL, Inoue K, Berna MJ, Garner CO, Gelfanova V, Dean RA, Siemers ER, Holtzman DM, Farlow MR, Blair IA.

Rapid Commun Mass Spectrom. 2006;20(24):3723-35.

PMID:
17117458
3.

Comparison of two different methods for measurement of amyloid-β peptides in cerebrospinal fluid after BACE1 inhibition in a dog model.

Borghys H, Jacobs T, Van Broeck B, Dillen L, Dhuyvetter D, Gijsen H, Mercken M.

J Alzheimers Dis. 2014;38(1):39-48. doi: 10.3233/JAD-130599.

PMID:
23948925
4.

A quantitative analysis of spontaneous isoaspartate formation from N-terminal asparaginyl and aspartyl residues.

Güttler BH, Cynis H, Seifert F, Ludwig HH, Porzel A, Schilling S.

Amino Acids. 2013 Apr;44(4):1205-14. doi: 10.1007/s00726-012-1454-0.

PMID:
23344882
5.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
6.

Analysis of isoaspartate in peptides by electrospray tandem mass spectrometry.

Lehmann WD, Schlosser A, Erben G, Pipkorn R, Bossemeyer D, Kinzel V.

Protein Sci. 2000 Nov;9(11):2260-8.

7.

Isoaspartate-containing amyloid precursor protein-derived peptides alter efficacy and specificity of potential beta-secretases.

Böhme L, Hoffmann T, Manhart S, Wolf R, Demuth HU.

Biol Chem. 2008 Aug;389(8):1055-66. doi: 10.1515/BC.2008.125.

PMID:
18979630
8.

Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease.

Portelius E, Zhang B, Gustavsson MK, Brinkmalm G, Westman-Brinkmalm A, Zetterberg H, Lee VM, Trojanowski JQ, Blennow K.

Neurodegener Dis. 2009;6(5-6):258-62. doi: 10.1159/000264639.

9.

Isoaspartate formation and neurodegeneration in Alzheimer's disease.

Shimizu T, Watanabe A, Ogawara M, Mori H, Shirasawa T.

Arch Biochem Biophys. 2000 Sep 15;381(2):225-34. Review.

PMID:
11032409
10.

Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease.

Roher AE, Lowenson JD, Clarke S, Wolkow C, Wang R, Cotter RJ, Reardon IM, Zürcher-Neely HA, Heinrikson RL, Ball MJ, et al.

J Biol Chem. 1993 Feb 15;268(5):3072-83.

11.

Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.

Goldstein LE, Muffat JA, Cherny RA, Moir RD, Ericsson MH, Huang X, Mavros C, Coccia JA, Faget KY, Fitch KA, Masters CL, Tanzi RE, Chylack LT Jr, Bush AI.

Lancet. 2003 Apr 12;361(9365):1258-65.

PMID:
12699953
12.

Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains.

Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE.

J Biol Chem. 2001 Apr 20;276(16):12991-8.

13.

Qualification of a surrogate matrix-based absolute quantification method for amyloid-β₄₂ in human cerebrospinal fluid using 2D UPLC-tandem mass spectrometry.

Korecka M, Waligorska T, Figurski M, Toledo JB, Arnold SE, Grossman M, Trojanowski JQ, Shaw LM.

J Alzheimers Dis. 2014;41(2):441-51. doi: 10.3233/JAD-132489.

14.

Identification of isomerization and racemization of aspartate in the Asp-Asp motifs of a therapeutic protein.

Zhang J, Yip H, Katta V.

Anal Biochem. 2011 Mar 15;410(2):234-43. doi: 10.1016/j.ab.2010.11.040.

PMID:
21130067
15.

The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.

Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E.

Neurosci Lett. 2014 Jun 24;573:7-12. doi: 10.1016/j.neulet.2014.04.041. Erratum in: Neurosci Lett. 2015 Jul 10;599():67-8.

PMID:
24796810
17.

Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimer's disease determined by protein biochip technology.

Maddalena AS, Papassotiropoulos A, Gonzalez-Agosti C, Signorell A, Hegi T, Pasch T, Nitsch RM, Hock C.

Neurodegener Dis. 2004;1(4-5):231-5.

PMID:
16908995
18.

Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome.

Portelius E, Hölttä M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, Herukka SK, Blennow K, Mattsson N.

Neuromolecular Med. 2014 Jun;16(2):510-6. doi: 10.1007/s12017-014-8302-1.

PMID:
24740518
19.

Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid.

Halim A, Brinkmalm G, Rüetschi U, Westman-Brinkmalm A, Portelius E, Zetterberg H, Blennow K, Larson G, Nilsson J.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11848-53. doi: 10.1073/pnas.1102664108.

20.

Site-specific aspartic acid isomerization regulates self-assembly and neurotoxicity of amyloid-β.

Sugiki T, Utsunomiya-Tate N.

Biochem Biophys Res Commun. 2013 Nov 15;441(2):493-8.

PMID:
24383085
Items per page

Supplemental Content

Support Center